Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Treatment of AIDS Vacuolar Myelopathy With Methionine
This study has been completed.
Sponsored by: National Institute of Neurological Disorders and Stroke (NINDS)
Information provided by: National Institute of Neurological Disorders and Stroke (NINDS)
ClinicalTrials.gov Identifier: NCT00032695
  Purpose

The purpose of this study is to determine whether methionine, an amino acid present in low doses in the normal diet, can improve myelopathy or stop its progression.


Condition Intervention Phase
Myelopathy
AIDS-Myelopathy
AIDS Vacuolar Myelopathy
Drug: methionine
Phase III

Drug Information available for: Methionine
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control

Further study details as provided by National Institute of Neurological Disorders and Stroke (NINDS):

Estimated Enrollment: 56
Detailed Description:

Myelopathy is usually a late complication of AIDS, and until recently its symptoms were rarely recognized, masked by the general state of disability or the presence of other neurological complications. With prolonged survival and improved quality of life of HIV-infected patients, myelopathy is increasingly becoming a common source of disability. The cause of AIDS-myelopathy is unknown, but it is probably an indirect effect of the long-term presence of the HIV virus in the nervous system rather than the result of a direct infection. The purpose of this study is to determine whether methionine, an amino acid present in low doses in the normal diet, can improve myelopathy or stop its progression.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Between 18 and 80 years of age

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00032695

Locations
United States, New York
Beth Israel Medical Center
New York, New York, United States, 10003
Sponsors and Collaborators
Investigators
Principal Investigator: Alessandro Di Rocco, MD
  More Information

Study ID Numbers: R01NS35745
Study First Received: March 28, 2002
Last Updated: May 12, 2006
ClinicalTrials.gov Identifier: NCT00032695  
Health Authority: United States: Federal Government

Keywords provided by National Institute of Neurological Disorders and Stroke (NINDS):
myelopathy
AIDS-myelopathy
AIDS vacuolar myelopathy
methionine

Study placed in the following topic categories:
Virus Diseases
Sexually Transmitted Diseases, Viral
Spinal Cord Diseases
HIV Infections
Sexually Transmitted Diseases
Acquired Immunodeficiency Syndrome
Central Nervous System Diseases
Retroviridae Infections
Immunologic Deficiency Syndromes

Additional relevant MeSH terms:
RNA Virus Infections
Slow Virus Diseases
Immune System Diseases
Nervous System Diseases
Lentivirus Infections

ClinicalTrials.gov processed this record on January 16, 2009